Antileishmanial potential of a marine sponge Haliclona oculata against experimental visceral leishmaniasis by Lakshmi, vijai et al.
187
Document heading             doi:10.12980/JCLM.3.2015APJTB-2014-0087                  ©2015 by the Journal of Coastal Life Medicine. All rights reserved.
Antileishmanial potential of a marine sponge Haliclona oculata against experimental visceral 
leishmaniasis 
Vijai Lakshmi1*, Prashant Khare2, Pragya Misra2, Mahendra Nath Srivastava3, Anuradha Dube2
1Divisions of Medicinal & Process Chemistry, CSIR-Central Drug Research Institute, Lucknow-226 001, India
2Divisions of Parasitology,CSIR-Central Drug Research Institute, Lucknow-226 001, India
3Divisions of Botany CSIR-Central Drug Research Institute, Lucknow-226 001, India
Journal of Coastal Life Medicine 2015; 3(3): 187-192
Journal of Coastal Life Medicine
    *Corresponding author: Dr. Vijai Lakshmi, Department of Biochemistry, King 
George Medical University, Lucknow-226003, India.
     E-mail: vijlakshmius@yahoo.com
     Tel: 91-0522-2254604
    Foundation Project: Supported by MOES, New Delhi (Grant number SSP003).
1. Introduction
    Leishmaniasis with a group of clinical manifestations caused 
by approximately 20 Leishmania species, has remained a major 
health problem in 88 tropical and subtropical countries of the 
world[1]. Visceral leishmaniasis (VL), also known as kala-azar, 
is the most severe in all the forms of leishmaniasis. It is caused 
by members of Leishmania donovani (L. donovani) complex, 
resulting in fever, hepatosplenomegaly, cachexia, and blood 
cytopenia. VL has also been emerging as an opportunistic infection 
in individuals carrying HIV[2]. The chemotherapy of VL has been 
undermined by resistance, variable efficacy, toxicity, parenteral 
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Objective: To evaluate the antileishmanial activity of a marine sponge Haliclona oculata. 
Methods: The crude methanol extract was prepared from the freshly collected sponge and its 
three fractions were also prepared by maceration method. The antileishmanial activity of these 
extract and fractions was tested against Leishmania donovani. 
Results: The antileishmanial activity was tested both in vitro and in vivo. The crude methanol 
extract exerted almost complete inhibition of promastigotes (81.0%依6.9%) and 78.8%依
5.2% inhibition of intracellular amastigotes at 100 μg/mL with IC50 values of 29.5 μg/mL and 40.6 
μg/mL, respectively. The treatment of 500 mg/kg (p.o.) of the crude methanol extract for 5 d for 
Leishmania donovani infected hamsters resulted in 78.35%依10.20% inhibition of intracellular 
amastigotes. At a lower dose (250 mg/kg), it exhibited poor efficacy. Among the fractions, 
highest in vitro (>75%) and in vivo (84.3%依10.2%) antileishmanial activity was observed in 
n-chloroform fraction with IC50 values of 54.2 μg/mL and 61 μg/mL against promastigotes 
and intracellular amastigotes, respectively. Hexane fraction and n-butanol (both insoluble and 
soluble) fractions were found inactive in vitro and in vivo. 
Conclusions: Our findings indicate that this marine sponge has the potential to provide new 
insight toward development of an effective antileishmanial agent and, hence, more exhaustive 
studies are needed for exploiting the vast marine resources of the world to combat the scourge 
of several parasitic diseases.
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administration, and requirement for long courses of administration. 
In India, sodium antimony gluconate is no longer useful as a drug 
because more than 64% of VL patients fail to respond or promptly 
relapse due to development of drug resistance in the parasite[3]. 
Alternative chemotherapeutic treatments with amphotericin B 
and its lipid formulation have severe limitations due to their toxic 
effect and prohibitive cost of treatment. There is an urgent need for 
new chemotherapeutic drugs for the treatment of these diseases, 
which mainly affect people in developing countries. With the recent 
emphasis of the World Health Organization on the development of 
antileishmanial agents from natural products, an urgent search for a 
drug derived from marine flora and fauna as well as from terrestrial 
plants has been initiated.
   Exploiting drug from marine resources offers an unprecedented 
opportunity for their pharmacological exploration and, hence, has 
received great attention during recent years for natural product 
chemistry, a promising new area of study. Secondary metabolites 
produced in marine organisms could be the source of bioactive 
substance and useful in modeling compounds for drugs[4,5]. Marine 
microorganisms, whose immense genetic and biochemical diversity 
is beginning to be appreciated, are likely to become a rich source for 
the discovery of more effective drugs.
   Marine sponges are shown to exhibit antibacterial, insecticidal, 
antiviral, and antiplasmodial activities[6,7]. Antifilarial activity of 
Haliclona species has also been reported[8].
   Few chemical compounds have been reported from marine 
sponges[9-12]. Some marine sponges are reported to possess 
antileishmanial activity. These sponges include Amphimedon viridis, 
Acanthostrongylophora specie, Neopetrosia specie, Plakortis 
angulospiculatus, and Pachymatisma johnstonii[6,13-15]. However, 
the antileishmanial compounds isolated from marine resources is 
still limited. 
   We have earlier reported antileishmanial activity of a marine 
sponge, Haliclona exigua (Kirkpatrick) (H. exigua) of the Indian 
coast. This sponge is found in Vallai Island, Setukarai, Gulf of 
Mannar, Ramnathpuram and Tamil Nadu coasts of India. It is 
sedentary and remains attached to sea bottom by masses of spicules. 
Its colonies are asymmetrical, brownish yellow and ranges from 4 
to 10 cm. These colonies are attached on the dead coral stones in 
shallow water areas at the depth of 3-6 m in subtidal region. In the 
present study, we have evaluated another species of Haliclona, i.e. 
Haliclona oculata (H. oculata) and its various fractions for their 
antileishmanial activity both in vitro as well as in vivo.
2. Material and methods
2.1. Collection of the sponge material
   The H. oculata, a marine sponge, was collected from Kursadai 
Islands, Ramnathpuram Tamil Nadu in the month of February. 
Specimen sample (voucher specimen Number 476) has been 
preserved in the herbarium of the Botany Division, Central Drug 
Research Institute, Lucknow, India.
2.1. Extraction, fractionation and isolation procedure
   Freshly collected sponge H. oculata (2 kg) was cut into small 
pieces and extracted with methanol (4伊4 L) at room temperature. 
The combined extract was filtered and concentrated under reduced 
pressure below 45 °C in a rotavapor to a viscous mass (45 g). The 
residual was further extracted with 50% methanol-chloroform (4伊
4 L) and the combined extract was filtered and concentrated under 
reduced pressure as above to a green viscous mass (35 g) and the 
residual was removed.
   The methanol extract (25 g) was fractionated into hexane (1.6 g), 
chloroform (2.0 g), n-butanol soluble (9.6 g) and n-butanol insoluble 
fractions (11.8 g). The chloroform fraction (1.9 g) was fractionated 
into eight fractions by column chromatography. The sub-fraction 
showing potent antileishmanial activity was analysed by Liquid 
chromatography–mass spectrometry analysis to indentify the pure 
chemical entity responsible for this activity[16-18].                                                                
2.2. Parasite culture
   The promastigotes of L. donovani (MHOM/80/Dd8) were grown in 
Roswell Park Memorial Institute-1640 medium supplemented with 
10% heat-inactivated foetal bovine serum (Sigma, USA), 100 IU/mL 
penicillin (Sigma, USA) and 100 μg/mL streptomycin (Sigma, USA) 
at 26°C. Transgenic parasites expressing green fluorescent protein 
(GFP) were cultured in the presence of 100 μg/mL of geneticin 
sulphate (G418).
2.3. Macrophage cell line culture and maintenance
   The adherent mouse macrophage cell line J774A.1 was maintained 
in Dulbecco’s modified Eagle’s medium (Sigma, USA) supplemented 
with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin 
and 100 μg/mL streptomycin at 37 °C in 5% CO2 in a humidified 
atmosphere.
2.4. Preparation of stock solutions and administration of test 
samples
   For in vitro testing, extract and fractions were solubilized in 
minimum volume of dimethyl sulphoxide (DMSO) before adding to 
sterile Roswell Park Memorial Institute-1640+10% fetal calf serum 
and stocked at a concentration of 1 mg/mL. The final concentration 
of DMSO never exceeded 0.1% in test medium, a concentration that 
has no effect on the growth of parasites or macrophage cells. For in 
vivo testing, required quantity of the extract/fractions were weighed, 
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and a suspension was made in Tween 20 or 10% ethanol or saline 
water by crushing them in a pestle mortar, and final concentrations 
were made with sterile water. Test materials were administered as 
per standard procedures reported earlier[19].
2.5. Antipromastigote activity 
   Log phase transgenic GFP-expressing promastigotes (1×106 cells/
mL) were put into 48-well tissue culture plates (CellStar), and 
different concentrations (100, 50, 25 and 10 μg/mL) of standard 
drugs as well as test samples were administered. Untreated 
cells served as control. Each assay was performed in triplicate. 
At different time intervals (48-72 h) after treatment, cells were 
removed, washed in phosphate buffer solution (PBS), and analyzed 
in a FACSCalibur flow cytometry (Becton Dickinson, USA) equipped 
with a 15 mV, 488 nm, air-cooled argon laser with excitation at 488 
nm and emission at 515 nm. Ten thousand cells were acquired for 
each analysis. Multiparametric data were analyzed by Cell Quest 
software (Becton Dickinson). The inhibition of parasite growth was 
determined by comparing the fluorescence levels of drug treated 
parasites with that of untreated control parasites. Miltefosine was 
used as a reference drug.
2.6. Activity against intracellular amastigotes 
   J774A.1 macrophages were cultured in 24 well plates (CellStar), 
to a cell density of 105 cells/well and infected with late log phase 
transgenic GFP-expressing promastigotes at a multiplicity of 
infection of 10:1 (parasite/macrophage) and incubated at 37 °C in 
5% CO2 for 8-12 h. Wells were later washed thrice with incomplete 
medium to remove non phagocytosed parasites, and finally, the 
wells were supplemented with complete medium. At different time 
intervals (48-72 h) after treatment with the test samples (100, 50, 25 
and 10 μg/mL), cells were removed, washed in PBS, and analyzed in 
a FACSCaliber flow cytometry (Becton Dickinson, USA) equipped 
with a 15 mV, 488 nm, air-cooled argon laser with excitation at 488 
nm and emission at 515 nm. Ten thousand cells were acquired for 
each analysis. Multiparametric data were analyzed by Cell Quest 
software (Becton Dickinson). The inhibition of parasite growth was 
determined by comparing the fluorescence levels of treated parasites 
with that of untreated control parasites. 
2.7. Cytotoxicity assay
   In vitro cytotoxicity of H. oculata extract and fractions on J774A.1 
macrophages was assessed by colorimetric 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide reduction assay. Cells (105 
per milliliter) were incubated with 100 μg/mL of the test samples 
and incubated at 37 °C in 5% CO2 for 72 h. 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide at a final concentration of 
400 μg/mL was added and incubated further for 3 h at 24 °C. Cells 
were centrifuged at 4 500 r/min, and pellets were dissolved in DMSO 
before taking the absorbance at 540 nm. The mean percentage of 
post treatment viable cells was calculated relative to control, and 
results were expressed as the concentration inhibiting cell growth by 
50% (IC50).
2.8. Animal host
   Laboratory-bred male golden hamsters (Mesocricetus auratus) 
weighing 45-50 g were used as the experimental host. They were 
housed in climatically controlled rooms and fed with standard rodent 
food pellet (Lipton Ltd, Bombay) and water ad libitum. Experiments 
on the animals were performed following the guidelines of 
Institutional Animal Ethics Committee of the CDRI.
   Hamsters were infected intracardially with late log phase 
promastigotes of L. donovani. Briefly, promastigotes were harvested 
by centrifugation at 2 800 r/min for 15 min at 4 °C, washed thrice 
with PBS and resuspended in PBS to a concentration of 1伊108 per 0.1 
mL. Hamsters were inoculated intracardially with promastigotes in 
0.1 mL of PBS. Parasite burden was assessed on Day 20-Day 25 post-
infection by performing splenic biopsies as described previously[19]. 
Once the infection was established with promastigote form, further 
passages in hamsters were carried out with splenic amastigotes. For 
this, animals carrying 40-60 d infection were autopsied, their spleen 
removed aseptically, homogenized in PBS and centrifuged at 900 r/
min for 5 min at 4 °C to sieve out tissue debris. Supernatant was 
centrifuged at 2 500 r/min for 10 min, pellet washed twice with 
PBS. Animals were infected intracardially with 1伊107 amastigotes 
in 0.1 mL PBS. Animals carrying 25-30 d infection were employed 
for drug screening.
2.9. Leishmanicidal efficacy against experimental VL in 
golden hamsters  
 
   L. donovani-infected hamsters were administered with 500 mg/kg, 
250mg/kg and 100mg/kg of test samples by oral route. Miltefosine, 
the reference drug, was administered orally at a dose of 40 mg/
kg for 5 d. Splenic parasite loads in treated and untreated animals 
were determined on Day 7 post-treatment by performing splenic 
biopsies[19]. Impression smears were made on glass slides, air dried, 
fixed in absolute methanol, and stained with 10% Giemsa for 30 
min. Slides were counted for the number of amastigotes under the 
oil immersion objective (100×) of a phase-contrast micro-scope[20]. 
Percent parasite inhibition in treated animals was calculated using 
the formula
% inhibition =
AT-100
IT-TI
   where AT is the actual number of amastigotes per 100 spleen cell 
nuclei in treated animals, IT is the initial number of amastigotes per 
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100 spleen cell nuclei in treated animals, and TI is the times increase 
in untreated control animals.
2.10. Statistical analysis
   Two to three replicates were done in case where activity was 
observed for confirmation and results were expressed as mean依
SD. Statistical analyses were performed using Sigma Stat (V2.03) 
software. 
3. Results
   Because the chloroform sub-fraction possesses better efficacy, it 
was decided to isolate the pure chemical entity responsible for this 
activity. For this purpose, chloroform sub-fraction was subjected 
to HPLC-MS analysis wherein the presence of four compounds viz. 
mimosamycin, xestospongin-C, xestospongin-D and araguspongin-C 
were identified. 
3.1. Inhibitory effect of H. oculata on promastigotes 
   The effect of methanol extract, its fractions, and sub fraction was 
evaluated against promastigote form of transgenic L. donovani 
expressing GFP by flow cytometry. Methanol extract and chloroform 
fraction and its sub fraction were highly effective causing almost 
complete parasite death (IC50=29.5, 54.2, 36.5 μg/mL respectively) 
as evidenced by drastic parasite inhibition at a concentration of 100 
μg/mL (Table 1). At lower concentrations, there was still significant 
inhibition of promastigote growth. Hexane fraction was found 
inactive against promastigote at 100 and 50 μg/ mL. Hexane and 
n-butanol (insoluble and soluble) fractions were found to be inactive 
at 100 μg/mL and lower doses, as there was negligible decrease 
in fluorescence levels. The reference drug, miltefosine, exhibited 
complete inhibition of parasite multiplication (>90%; Table 1).
Table 1 
In vitro antileishmanial activity of H. oculata.
Extract and fractions
Concentration 
(μg/mL)
Activity against 
promastigotes
(%)
Activity against 
intracellular amastigotes
(%)
Methanol extract 100 81.0依6.9  78.8依5.2  
50 67.6依7.4  53.2依6.4  
25 Inactive Inactive
Hexane fraction of methanol 
extract
100 Inactive Inactive
50 Inactive Inactive
Chloroform fraction of 
methanol extract
100 79.0依3.7  74.6依4.2  
50 Inactive Inactive
Sub fraction of the active 
chloroform fraction
100  83.0依7.7  76.8依5.1  
50  57.2依8.4  52.2依4.0  
25 Inactive Inactive
n-Butanol soluble fraction of 
methanol extract
100 Inactive Inactive
50 Inactive Inactive
n-Butanol insoluble fraction of 
methanol extract
100 Inactive Inactive
50 Inactive Inactive
Meltifosine 40 96.0依2.7  90.3依4.7  
3.2. Inhibitory effect of H. oculata on intra-macrophage 
amastigotes
   The crude extract and its fractions were evaluated for their 
leishmanicidal effect on intracellular amastigotes. Methanol extract 
showed significant inhibition of intracellular amastigotes (78.8%依
5.2%) at a dose of 100 μg/mL (Table 1), whereas at 50 μg/mL, the 
inhibitory effect was 53.2%依6.4%. Its IC50 was 40.6 μg/mL (Table 
2) . Chloroform fraction resulted in 74.6%依4.2% inhibition of 
amastigotes growth at 100 μg/mL but was weakly active or inactive 
at lower doses. Similarly the subfraction of the active chloroform 
fraction exhibited 76.8%依5.1% and 52.2%依4.0% inhibition at the 
dose of 100 μg/mL and 50 μg/mL respectively. The hexane and 
n-butanol fraction was inactive at the doses of 100 and 50 μg/mL, 
respectively. 
Table 2 
IC50 values (μg/mL) of extract and fractions against promastigote and 
intracellular  amastigotes.
Extracts/fractions Promastigotes
Intracellular 
amastigote
Methanol extract 29.5 40.6
Chloroform fraction of methanol extract 54.2 61.0
Sub fraction of the active  chloroform fraction 36.5             42.3
3.3. Cytotoxic activities of H. oculata
   Crude methanol extract showed a cytotoxic effect against J774A.1 
cells with IC50 value of 34.6 μg/mL, whereas the extracts and pure 
compound were devoid of any cytotoxic effect (IC50>100 μg/mL).
3.4. Antileishmanial activity of H. oculata in hamsters
   Efficacy of the crude extract as well as its fractions was assessed 
against L. donovani infection in hamster model of VL. Methanol 
extract was found to be active and considerably good efficacy 
(78.35%依10.20%) was observed at the dose level of 500 mg/kg 
for 5 d. At 250 mg/kg for 5 d, it was inactive. Administration of 
chloroform fraction at a dose of 250 mg/kg for 5 d, p.o., resulted 
in 84.3%依10.2% inhibition (Table 3) of L. donovani but inactive 
at the dose of 100 mg/kg for 5 d. Similarly the subfraction of the 
active chloroform fraction was active and showed 78.35%依6.20% 
inhibition. At doses of 100 mg/kg for 5 d, it was found to be poor 
active (55.0%依2.2% inhibition), whereas hexane and n-butanol 
(insoluble and soluble) fractions were inactive (<50% parasite 
inhibition) at similar dose levels. Miltefosine was highly effective 
causing 93.6%依6.3% inhibition of L. donovani at 40 mg/kg for 5 d, 
p.o. 
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Table 3  
In vivo antileishmanial activity of H. oculata.
Extracts/Fractions Dose (mg/kg) % Suppression
Methanol extract 500 78.35依10.20
Chloroform fraction of methanol extract 250 84.30依10.20
100 Inactive
Sub fraction of the active chloroform fraction 250 78.35依6.20 
100 55.00依2.20 
Meltifosine 40 93.60依6.30   
4. Discussion
   There are many marine products possessing antiparasitic activity, 
but only few have the hope to reach the clinical trial stage. Some 
of the marine natural compounds, isolated from cone snails, corals, 
sponges, sea squirts, marine worms, bryozoans, sea slug, and sharks 
were used for treating fungal infection, tuberculosis, nematode 
infection, malarial infection, bacterial infection, viral infection, 
pain management, cancer, and inflammation control. Few marine 
sponges are reported to exhibit diverse range of bioactivities 
including cytotoxicity, insecticidal, antibacterial, anti-inflammatory, 
anti-infective, and antiparasitic, as well as the exciting curative 
activity against malaria in animal models[6,15]. For example, 
illimaquinone, isolated from marine sponge, has been shown to 
have an antiproliferative effect against Leishmania. Similarly, 
manzamines, unique β-carboline alkaloids, were first reported from 
the genus Haliclona. We also have demonstrated considerably good 
antileishmanial activity, though, in the crude extract of H. exigua and 
its fraction only. The pure compound was ineffective. In the process, 
we thought it is worthwhile to explore the potential of another 
species of Haliclona i.e. H. oculata for its antileishmanial activity. 
   In the present study, crude methanolic extract of H. oculata and 
its chloroform fraction as well as sub-fraction showed considerably 
good inhibitory activity against both promastigote and intracellular 
amastigote forms of L. donovani but was inferior to the activity of 
standard drug miltefosine. Activity in macrophage-amastigote system 
is encouraging because the morphology and biochemistry of the 
intracellular amastigotes is similar to that of the clinical amastigote 
stage. The other fractions like hexane fraction and n-butanol fraction 
(soluble and insoluble) were ineffective against both the stages.
   The antileishmanial activity of the potential extract of H. oculata 
i.e. methanolic and its chloroform fraction and sub-fraction was 
validated in male golden hamsters infected with L. donovani. 
Hamsters have proven to be a good animal model for the study of 
human VL, as it presents a progressive disease similar to human 
kala-azar[21]. Methanolic extract exhibited good efficacy at 500 mg/
kg. The infected animals tolerated the treatment with no drastic 
changes in body and organ weight in treated group as compared 
to the untreated group. The activity of chloroform fraction at the 
dose of 250 mg/kg for 5 d, p.o., was found to be superior to the 
methanolic extract, indicating that the antileishmanial principles 
of this plant are present in higher quantity in this fraction. The 
activity of sub-fraction of chloroform fraction was equal to that of 
methanolic extract and its chloroform fraction. 
   In our earlier studies with H. exigua one alkaloid identical to 
araguspongin C was found to have moderate activity in vitro and 
was ineffective in vivo. These studies were limited by low yield of 
the compounds. Nevertheless the excellent activity of the chloroform 
sub-fraction could be due to the combined or synergistic effects of 
more than one component. The antileishmanial efficacy exerted in 
this study by H. oculata was not comparable to the potent action of 
miltefosine (standard drug); however, its effective action on in vitro 
stages and moderate action in hamsters combined with its natural 
origin makes this marine product worth pursuing as a potential agent 
against leishmaniasis. The present findings warrant the exploration 
of more marine flora and fauna in order to locate the active principle 
for their antileishmanial potential. 
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Comments 
Background
   Leishmaniasis is a dangerous parasitic disease which is spread 
by the bite of phlebotomine sand flies. Conventional methods for 
treatment of leishmaniasis are not always effective, therefore the 
development of new methods based on the use of natural sources is 
of a priority and highly relevant.
  
Research frontiers
   The present manuscript depicts antileishmanial activity of extracts 
of marine sponge species H. oculata and its various fractions both in 
vitro as well as in vivo. Authors demonstrate that methanol extract 
and chloroform fractions and its sub fraction were highly effective 
causing almost complete parasite killing as evidenced by parasite 
inhibition.
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Related reports
   Marine sponges are shown to exhibit antibacterial, insecticidal, 
antiviral, and antiplasmodial activities. Antifilarial activity of 
Haliclona species has also been reported. Few chemical compounds 
have been reported from marine sponges. Some marine sponges are 
reported to possess antileishmanial activity.
Innovations and breakthroughs
   The antileishmanial efficacy exerted in this study by H. oculata 
was not comparable to the potent action of miltefosine (standard 
drug); however, its effective action on in vitro stages and moderate 
action in hamsters combined with its natural origin makes this 
marine product worth pursuing as a potential agent against 
leishmaniasis.
  
Applications
   The present findings warrant the exploration of more marine 
flora and fauna in order to locate the active principle for their 
antileishmanial potential.   
Peer review
   The manuscript shows possibility of exploration of more marine 
flora and fauna in order to locate the active principle for their 
antileishmanial potential. The obtained data indicate that marine 
sponge has the potential to provide new lead toward development 
of an effective antileishmanial agent and, hence, calls for more 
exhaustive studies for exploiting the vast world of marine resources 
to combat the scourge of several parasitic diseases.
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